



# The TLR7/9 adaptors TASL and TASL2 mediate IRF5-dependent antiviral responses and autoimmunity in mouse

Received: 5 January 2024

Accepted: 14 November 2024

Published online: 24 January 2025

Ales Drobek <sup>1</sup>, Léa Bernaleau <sup>1</sup>, Maeva Delacrétaz <sup>1</sup>,  
Sandra Calderon Copete<sup>2</sup>, Claire Royer-Chardon<sup>3</sup>, Mélissa Longepierre<sup>1</sup>,  
Marta Monguió-Tortajada <sup>1</sup>, Jakub Korzeniowski <sup>1</sup>, Samuel Rotman <sup>3</sup>,  
Julien Marquis <sup>2</sup> & Manuele Rebsamen <sup>1</sup>✉


**Is the TASL–SLC15A4–IRF5 pathway  
essential for antiviral defense and/or  
autoimmunity?**

Axel Croonenbroek, Manon Sierra


# Introduction

# Innate immune sensing of nucleic acids

## Cytosol



## Endosomal compartment




## Introduction

# TLR7/9–IRF5 signaling in infection

→ Protective response in viral or bacterial infection


- **TLR7** detect viral RNA
- **TLR9** detect CpG-rich DNA which is typical of bacterial or viral DNA



## Introduction

# Discovery of the SLC15A4–TASL complex controlling IRF5 activation

- 1) SLC15A4 recruits TASL to the lysosomal surface
- 2) TLR7/9 recruit the adaptor MyD88
- 3) MyD88 recruit a kinase → phosphorylate TASL (at the pLxIS motif)
- 4) Phospho-TASL recruits and activates IRF5
- 5) Leads to IRF5 nuclear translocation and gene activation




## Introduction

# TLR7/9–IRF5 signaling in autoimmunity

→ BUT when mistakenly recognizes self nucleic acids → pathogenic

- Overactivation of TLR7/9 and IRF5 = hallmark of several autoimmune diseases → like **systemic lupus erythematosus (SLE)**
- In lupus, self-DNA or RNA released from apoptotic cells activates pDCs and B cells → autoantibodies + chronic IFN signaling



## Introduction

# Knowledge gaps

<b>Known before the study</b>	<b>Unknown / Open questions</b>
SLC15A4-TASL complex activates IRF5 downstream of TLR7/9 in human cells	Does this signaling pathway also function in mice in vivo ?
TASL binds to SLC15A4 via its N-terminal region and recruits IRF5 via the PLxIS motif	Is TASL the only adaptor linking SLC15A4 to IRF5 ?
Human genetic studies associate SLC15A4, TASL and IRF5 with lupus (SLE)	Can loss of this pathway protect against lupus-like autoimmunity in vivo ?

## Methods

# Generation of mouse models to study the SLC15A4-TASL pathway


Genotype	Deleted gene	Purpose
<i>feeble</i>	SLC15A4	Loss of entire pathway
TASL <sup>KO</sup>	<i>Tasl</i>	Test role of TASL
TASL2 <sup>KO</sup>	<i>Gm6377</i>	Test role of TASL2 and test of redundancy
TASL <sup>DKO</sup>	Both <i>Tasl</i> and <i>Gm6377</i>	Check full loss of IRF5 activation, mimicking <i>feeble</i>



The knock-out mice have been generated using CRISPR-Cas9 and gRNAs injected into pronuclei of fertilized C57Bl6J mouse zygotes

## Methods

# Assessing IRF5 activation and cytokine responses in immune cells



**B cell** : secretion of antibodies and cytokines like IL-6, TNF $\alpha$  and Type I Interferons (IFN $\alpha$  and IFN $\beta$ )


**pDC (plasmacytoid dendritic cell)** : secretion of most of the Type I Interferons (IFN $\alpha$  and IFN $\beta$ ), as well as TNF $\alpha$ , IL-6 and IL-12p40

## Results


# SLC15A4 is essential for TLR7/9-induced IRF5 activation

activation

Stimulation of BM-pDCs



Stimulation of splenic B cells



**R848:** TLR7 agonist, mimics viral ssRNA



**CpG-B:** TLR9 agonist, mimics bacterial/viral DNA

## Results

# TASL deficiency impairs IRF5 activation

WT and TASL<sup>KO</sup> BM-pDC stimulated with R848 for the indicated time

→ TASL is a critical adaptor linking SLC15A4 to IRF5 activation




## Results

# TASL<sup>KO</sup> impairs IRF5 activation and cytokine production

WT and TASL<sup>KO</sup> BM-pDC stimulated with R848 for the indicated time

→ Without TASL the TLR7/9 transcriptional responses are largely blocked




Cytokine production was analyzed by paired RT-qPCR

## Results

# Residual IRF5 activation in TASL<sup>KO</sup> cells suggests another adaptor

WT and TASL<sup>KO</sup> BM-pDC stimulated with R848 for the indicated time



What causes this residual activation?

## Results


# Identification of TASL2, a functional paralogue of TASL

*Gm6377* → encodes TASL2

TASL2 can : bind mSLC15A4  
+ substitute TASL in mice

→ TASL2 is a functional  
paralogue of TASL in  
mice


Transiently transfected  
HEK293T cells



Immunoprecipitates (IP, Strep-tag St)  
and whole-cell extracts (XT)

**V5-tagged:** Tag TASL, TASL2  
**HA-tagged:** hS15A4 or mS15A4

RAW 264.7 cell lines




Immunoblots

**sgRen:** Control  
**sgTasl:** TASL<sup>KO</sup>


## Results

# TASL and TASL2 act redundantly to control IRF5 activation

WT, TASL<sup>KO</sup>, TASL<sup>2KO</sup> BM-pDC stimulated with R848 or CpG-B for the indicated time




**R848:** TLR7 agonist, mimics viral ssRNA  
**CpG-B:** TLR9 agonist, mimics bacterial/viral DNA




→ TASL and TASL2 are functionally redundant

# Results

## Global transcriptional effects confirm loss of IRF5-driven programs



DEG : differentially expressed genes  
Each row is a different gene




Gene ontology enrichment analysis (GO enrichment)

Comparison of **gene expression profiles** after stimulating with TLR7 or TLR9 agonists to **identify which genes are activated by nucleic acid sensing pathways**

## Results

# TASL/TASL2 are essential for in vivo TLR7/9 cytokine responses




- TLR7/9 agonist stimulation triggers IRF5-dependent cytokine secretion, which is **abolished in TASL<sup>KO</sup>, TASL<sup>DKO</sup> and *feeble* mice**
- **TASL2<sup>KO</sup> had no or only marginal effect on these responses**

We can observe that the **production of TNFα is not fully impaired** in TASL<sup>KO</sup>, TASL<sup>DKO</sup> and *feeble* mice → possible **redundancy** from independent signalling pathway (MAPK and NF-κB)

## Methods


# Evaluating antiviral responses in vivo




Antiviral response of WT,  $TASL^{KO}$ ,  $TASL2^{KO}$ ,  $TASL^{DKO}$  and *feeble* mice

# Results

## TASL<sup>DKO</sup> mice fail to control chronic LCMV infection




Blood viremia at different timepoints → **TASL<sup>DKO</sup> and *feeble* fail to clear the viral infection** after 4 months



**Impairment of triple cytokine producing cells** in all KO, with the biggest being TASL<sup>DKO</sup> and *feeble*

## Methods

# Pristane model to induce lupus autoimmunity in mice





→ Autoantibodies form immune complexes → deposit in the kidney  
⇒ glomerulonephritis = hallmark of lupus



## Results

# Loss of TASL protects against lupus-like

Autoimmunity



- WT
- TASL<sup>KO</sup>
- TASL<sup>DKO</sup>
- *feeble*




- Sm/RNP : antibodies that target a complex of proteins and small nuclear ribonucleoprotein (snRNP) molecules
- Ago2 : Argonaute 2 protein, a crucial component of the RNA-induced silencing complex (RISC)

Pristane induces autoimmune disease

## Results


# Loss of TASL Prevents Autoantibody Deposition in Lupus Model




Antinuclear antibodies in serum  
6 months after pristane  
injection  
→ absence of autoantibodies in  
the KO

## Discussion

# Targeting the SLC15A4-TASL axis: a promising strategy against lupus



## TASL inhibited pathway



## Discussion

# Main limitation and futur perspective

- TASL inhibition → strong protection in lupus but loss of antiviral defense
- Can we design **selective inhibitors** that disrupt the SLC15A4–TASL interface only in autoreactive B cells or pDCs, while preserving antiviral responses?

**Thank you for your  
attention !**

Discussion

## **Limitations**

- TASSL inhibition → strong protection in lupus but loss of antiviral defense
- Focused mainly on TLR7/9 and IRF5 → other IRFs or sensors not tested

## Discussion

# Future perspectives

- 1) Can we design **selective inhibitors** that disrupt the SLC15A4–TASL interface only in autoreactive B cells or pDCs, while preserving antiviral responses?
- 2) Does the **absence of TASL2 in humans** make our immune system more dependent on TASL, and could this explain our higher susceptibility to lupus?
- 3) Are there **other adaptor proteins** interacting with SLC15A4 that could modulate signaling in different contexts?